Tag: adcs

Delta-Like Ligand 3 Targeted Therapies Market Overview

The market for delta-like ligand 3 (DLL3) targeted therapies is rapidly expanding due to the rising prevalence of small cell lung cancer (SCLC) and neuroendocrine tumors. Advancements in antibody-drug conjugate (ADC) technology and increased clinical trial activity are driving the development of DLL3-targeted therapies. Strategic collaborations and growing interest from biopharma companies are accelerating market […]

NextCure Enters China’s ADC Market with $745M Simcere Agreement

In a significant move that underscores the ascendant allure of Antibody-Drug Conjugates (ADCs) in China, Maryland-based biotech firm, NextCure, has inked a $745 million partnership with Simcere Pharmaceutical Group. This pivotal deal not only elevates NextCure’s oncology portfolio, but it also mirrors the larger biopharma trend where companies are channeling substantial investments into acquiring assets […]

Revolutionizing Cancer Therapy: ASCO 2025 Highlights

Antibody Drug Conjugates (ADCs) have been a game-changer in precision oncology over the past 25 years. Originally a bold concept, ADCs have now become a cornerstone in treating both blood cancers and solid tumors. The latest generation of ADCs features advanced technologies like smarter linkers, novel payloads, and higher drug-antibody ratios, pushing the boundaries of […]

Analysts’ Insights on BioNTech’s Future

BioNTech, a Germany-based biotech company, is at the forefront of developing cancer therapeutics and vaccines for infectious diseases, including COVID. With a diverse oncology pipeline that includes mRNA-based drugs, cell therapies, bispecific antibodies, and ADCs, BioNTech has established partnerships with major pharmaceutical companies like Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Its COVID vaccine, Comirnaty, […]